ACS Medicinal Chemistry Letters
Letter
Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a novel class of
phosphodiesterase 10A inhibitors and identification of clinical
candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-
methyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
J. Med. Chem. 2009, 52, 5188−96.
(17) Zoraghi, R.; Corbin, J. D.; Francis, S. H. Properties and
functions of GAF domains in cyclic nucleotide phosphodiesterases and
other proteins. Mol. Pharmacol. 2004, 65, 267−78.
HPβCD, (2-hydroxypropyl)-beta-cyclodextrin [128446-35-5];
hLM, human liver microsomes; i.v., intravenous; n.m., not
measured; PDE, phosphodiesterase; p.o., per os (oral); s.c.,
subcutaneous; s.d., standard deviation; rLM, rat liver micro-
somes; t1/2, half-life; tmax, time at maximum concentration; Vdss,
steady-state volume of distribution; Vdz, apparent volume of
distribution
REFERENCES
■
(1) Francis, S. H.; Blount, M. A.; Corbin, J. D. Mammalian cyclic
nucleotide phosphodiesterases: molecular mechanisms and physio-
logical functions. Physiol. Rev. 2011, 91, 651−90.
(2) Rosman, G. J.; Martins, T. J.; Sonnenburg, W. K.; Beavo, J. A.;
Ferguson, K.; Loughney, K. Isolation and characterization of human
cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phospho-
diesterase. Gene 1997, 191, 89−95.
(3) Lakics, V.; Karran, E. H.; Boess, F. G. Quantitative comparison of
phosphodiesterase mRNA distribution in human brain and peripheral
tissues. Neuropharmacology 2010, 59, 367−74.
(4) Gomez, L.; Breitenbucher, J. G. PDE2 inhibition: potential for
the treatment of cognitive disorders. Bioorg. Med. Chem. Lett. 2013, 23,
6522−27.
(5) Schmidt, C. J. Phosphodiesterase inhibitors as potential cognition
enhancing agents. Curr. Top. Med. Chem. 2010, 10, 222−30.
(6) Sanderson, T. M.; Sher, E. The role of phosphodiesterases in
hippocampal synaptic plasticity. Neuropharmacology 2013, 74, 86−95.
(7) Maurice, D. H.; Ke, H.; Ahmad, F.; Wang, Y.; Chung, J.;
Manganiello, V. C. Advances in targeting cyclic nucleotide
phosphodiesterases. Nat. Rev. Drug Discovery 2014, 13, 290−314.
́
(8) Andres, J.-I.; Buijnsters, P.; De Angelis, M.; Langlois, X.;
Rombouts, F.; Trabanco, A. A.; Vanhoof, G. Discovery of a new series
of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/
phosphodiesterase 10 (PDE2/PDE10) inhibitors. Bioorg. Med. Chem.
Lett. 2013, 23, 785−90.
́
(9) Buijnsters, P.; Andres, J.-I.; De Angelis, M.; Langlois, X.;
Rombouts, F.; Sanderson, W.; Tresadern, G.; Ritchie, A.; Trabanco,
A.; Vanhoof, G.; Van Roosbroeck, Y. Structure-based design of a
potent, selective, and brain penetrating PDE2 inhibitor with
demonstrated target engagement. ACS Med. Chem. Lett. 2014, 5,
1049−1053.
(10) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.;
Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.;
Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new
approach for rapid, accurate docking and scoring. 1. Method and
assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739−1749.
(11) Synthetic protocols are provided as SI. Compounds 6 and 7
have been previously reported in: Joergensen, M.; Bruun, A. T.;
Rasmussen, L. K. Preparation of pyridine compounds useful for
treating neurological and psychiatric disorders. PCT Int. Appl., WO
2013034761 A1, 2013.
(12) Malamas, M. S.; Ni, Y.; Erdei, J.; Stange, H.; Schindler, R.;
Lankau, H.-J.; Grunwald, C.; Fan, K. Y.; Parris, K.; Langen, B.;
Egerland, U.; Hage, T.; Marquis, K. L.; Grauer, S.; Brennan, J.;
Navarra, R.; Graf, R.; Harrison, B. L.; Robichaud, A.; Kronbach, T.;
Pangalos, M. N.; Hoefgen, N.; Brandon, N. J. Highly potent, selective,
and orally active phosphodiesterase 10A inhibitors. J. Med. Chem.
2011, 54, 7621−7638.
(13) Jorgensen, W. L. Efficient drug lead discovery and optimization.
Acc. Chem. Res. 2009, 42, 724−733.
(14) Chodera, J. D.; Mobley, D. L.; Shirts, M. R.; Dixon, R. W.;
Branson, K.; Pande, V. S. Alchemical free energy methods for drug
discovery: Progress and challenges. Curr. Opin. Struct. Biol. 2011, 21,
150−160.
(15) StarDrop Optibrium, Ltd.: Cambridge, U.K.; http://www.
(16) Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.;
Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.;
O’Connor, R.; Pandit, J.; Proulx-Lafrance, C.; Schmidt, A. W.;
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX